BofA sees opportunity for Toast to capture additional market share
Toast Inc (NYSE:TOST) was initiated with a Buy rating and $26 price target by BofA analysts in a note Thursday. The analysts said their checks at last week's National Restaurant...
|
|
|
Name
|
Last
|
High
|
Low
|
Chg
|
Chg%
|
Volume
|
Time
|
|---|---|---|---|---|---|---|---|---|---|
| Jdgroup | 3,386 | 3,391 | 3,373 | 0 | 0.00% | 0 | |||
| WG Wearne | 0 | 3 | 3 | 0 | 0.00% | 0 | |||
| CSG Holdings | 36 | 37 | 34 | 0 | 0.00% | 0 | |||
| RH Bophelo | 279 | 279 | 279 | +0 | +0.00% | 0 | |||
| KayDav Group Ltd | 125 | 125 | 125 | 0 | 0.00% | 0 | |||
| Workforce | 121 | 121 | 121 | 0 | 0.00% | 0 | |||
| Pepkor | 1,470 | 1,484 | 1,402 | +59 | +4.18% | 35.72M | |||
| African Rainbow | 625 | 625 | 585 | 0 | 0.00% | 46.11K | |||
| Arrowhead Properties Ltd B | 830 | 836 | 829 | 0 | 0.00% | 0 | |||
| Acsion | 670 | 715 | 670 | +20 | +3.08% | 130.00 |
|
|
|
Name
|
Last
|
High
|
Low
|
Chg
|
Chg%
|
Volume
|
Time
|
|---|---|---|---|---|---|---|---|---|---|
| Gold Fields ADR | 15.805 | 15.930 | 15.400 | +0.685 | +4.53% | 2.99M | |||
| Sibanye Gold ADR | 7.29 | 7.33 | 7.10 | +0.15 | +2.17% | 1.60M | |||
| Harmony Gold Mining | 4.825 | 4.880 | 4.705 | +0.115 | +2.44% | 2.21M | |||
| AngloGold Ashanti ADR | 24.83 | 25.16 | 24.45 | +0.63 | +2.60% | 1.44M | |||
| DRDGOLD ADR | 11.90 | 12.17 | 11.45 | +0.34 | +2.90% | 266.34K |
|
|
|
Name
|
Last
|
High
|
Low
|
Chg
|
Chg%
|
Volume
|
Time
|
|---|---|---|---|---|---|---|---|---|---|
| Nio A ADR | 7.57 | 7.64 | 7.00 | +0.04 | +0.51% | 58.87M | |||
| Alphabet C | 124.09 | 125.04 | 123.30 | +0.72 | +0.58% | 13.71M | |||
| JD.com Inc Adr | 35.05 | 35.29 | 33.26 | +2.44 | +7.50% | 13.37M | |||
| Spotify Tech | 153.77 | 153.96 | 149.07 | +4.87 | +3.27% | 567.72K | |||
| Tilray | 1.72 | 1.78 | 1.63 | +0.04 | +2.69% | 19.95M |
Equities News & Analysis
-
-
Elon Musk is accused of insider trading by investors in Dogecoin lawsuit
By Jonathan Stempel NEW YORK (Reuters) - Elon Musk is being accused of insider trading in a proposed class action by investors accusing the Tesla (NASDAQ:TSLA) Inc CEO of manipulating the...
-
Stellantis does not need Italy as a shareholder, says Chairman Elkann
On Thursday, John Elkann, the Chairman of Stellantis NV (NYSE:STLA), responded to business lobbyists' calls for Italy to invest directly in the company. Elkann made it clear that Stellantis...
-
Marvell Technology and Broadcom will continue to dominate ASIC chip market - JPMorgan
JPMorgan analysts believe Broadcom (NASDAQ:AVGO) and Marvell Technology (NASDAQ:MRVL) will continue to dominate the ASIC chip market. The analysts said in their note assessing the sector...
-
Global equities rise, U.S. yields fall after debt ceiling bill advances
By Chibuike Oguh New YORK (Reuters) - Global equities rose on Thursday after the U.S. House of Representatives passed a bill to raise the federal debt ceiling, while U.S. Treasury yields...
-
National Retailer Awards IZEA Influencer Marketing Contract
Orlando, Florida, June 01, 2023 (GLOBE NEWSWIRE) -- IZEA Worldwide, Inc. (NASDAQ: IZEA), the premier provider of influencer marketing technology, data, and services for the world’s leading...
-
Lucid's stock dips as automaker seeks $3B with help from Saudi's PIF
Shares of electric automaker, Lucid (NASDAQ:LCID) plummeted almost 15% at the open Thursday morning after the company announced after hours Wednesday that it plans to raise about $3 billion...
-
The Bear Cave releases Palantir short report, says it is 'an AI imposter'
Palantir (PLTR) shares have remained resilient Thursday, climbing over 1% despite The Bear Cave newsletter releasing a short report on the stock. The newsletter, written by Edwin Dorsey,...
-
nCino, Inc. guidance disappoints, shares tumble
nCino, Inc. (NASDAQ:NCNO) shares tumbled Thursday despite beating top and bottom-line consensus expectations in the first quarter. The financial technology firm {{erl-1163256||reported Q1...
-
AbbVie declines after Coherus launches Humira biosimilar at 85% discount
Shares of AbbVie (NYSE:ABBV) declined Thursday after Coherus BioSciences (NASDAQ:CHRS) said it plans to launch a biosimilar to blockbuster arthritis drug Humira in July at a list price of...
